A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Trial Profile

A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 22 Apr 2019 to 19 Apr 2021.
    • 13 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 24 Mar 2019.
    • 13 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top